Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

MPI, inviCRO, 3D Imaging Collaborate

By Drug Discovery Trends Editor | June 12, 2013

MPI Research, the largest single-site preclinical/early clinical contract research organization (CRO) globally, has announced a strategic partnership with inviCRO and 3D Imaging to unite world-class molecular imaging, radiochemistry, and informatics to accelerate drug discovery and development. This partnership represents a combination of integrated imaging solutions that is offered by no other CRO in the world.

Having already collaborated on more than 100 unique imaging projects, MPI Research, inviCRO, and 3D Imaging are aligning and expanding to meet the industry’s need for comprehensive imaging services in a single location. The new molecular imaging center, located at MPI Research, will provide drug developers with access to the first commercially available cyclotron facility immediately contiguous with vivarium facilities housing species ranging from mice to nonhuman primates.

Jack Hoppin, PhD, Co-founder and Managing Partner of inviCRO, stated, “No other commercial facility in the world can offer translational molecular imaging capabilities from mice to nonhuman primates, and carbon-11 to zirconium-89, under one roof. We believe that the scope and quality of image data generated through this alliance will vastly accelerate drug discovery and development programs.” 

Marc Berridge, PhD, President and founder of 3D Imaging, shared, “3D Imaging is excited to apply our custom tracer applications in a wide range of animal models, including nonhuman primates, with the benefit of state-of-the-art image analysis. We look forward to providing a uniquely powerful total imaging and translational solution to our Sponsors through this alliance with two highly respected and capable partners.”

Groundbreaking for the new imaging center in Mattawan, Michigan, will occur very soon, and the new physical site will open in Q2 of 2014, although many of the expanded imaging solutions, including nonhuman primate PET and CT imaging capabilities, will be available in July 2013.
 
According to MPI Research Chairman, President, and CEO, William U. Parfet, “We have joined the best minds in imaging to form this partnership and I look forward to showing Sponsors how we can assist them with their drug and device development programs by offering the best imaging solutions in the world. Through this partnership with our esteemed colleagues at inviCRO and 3D Imaging, our Sponsors can reduce development costs, improve candidate selection, and accelerate regulatory approval.” 

Date: June 11, 2013
Source: MPI Research


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE